Here is the latest stock price and chart of PFIZER. For more details, see the PFIZER company fact sheet and quarterly results. For a sector overview, read our pharmaceuticals sector report. Since small-cap stocks interest you, here's a proven approach on investing in small-cap stocks.
Today at 5 PM: Top 3 Stocks for 2022 Revealed
Live BSE Quotes | May 23, 2022 (Close) | ||
---|---|---|---|
Price (Rs)4,407.35 | Open (Rs) 4,368.15 | High (Rs) 4,497.55 | Low (Rs) 4,329.45 |
% Change1.27 | Volume 2,337 | Value (Rs) 10,343,867 | 52-Week H/L 6,164.80 / 4,077.80 |
Live NSE Quotes | May 24, 2022 9:07:41 AM | ||
---|---|---|---|
Price (Rs)4,400.00 | Open (Rs) 4,400.00 | High (Rs) 4,400.00 | Low (Rs) 4,400.00 |
% Change-0.27 | Volume 48 | Value (Rs) 211,200 | 52-Week H/L 6,175.00 / 4,071.40 |
Change | |||||
---|---|---|---|---|---|
1 Day 1.27% | 1 Month 2.18% | 3 Months 2.84% | 1 Year -15.92% | 5 Years (CAGR)* 20.87% | 10 Years (CAGR)* 14.26% |
* Compound Annual Growth Rate
Valuation | ||||
---|---|---|---|---|
EPS (Rs)* 128.38 | P/E Ratio (x) 34.33 | Market Cap (Rs m) 201,626.13 | P/BV (x) 8.43 | Dividend Yield (%) 0.28 |
*Trailing 12 months earnings, excluding extraordinary / exceptional items. | BSE Sensex | CNX Nifty |
S&P BSE SENSEX ![]() |
||||||
PERIOD |
PFIZER last traded price was down 0.3% to Rs 4,400.0 on the NSE. The total volume of shares traded was 0.0 m.
Overall, the broader S&P BSE HEALTHCARE Index was up by 0.2%. And the benchmark NIFTY 50 was at 16,225.6 (up 0.1%).
Over the last 30 days, the PFIZER share price is down 1.4%.
The current market capitalisation of PFIZER stands at Rs 201,626.13 m. For more information, check out the list of top 100 companies in India in terms of market cap.
As of March 2022, company promoters held 63.92% stake in PFIZER, with no shares having been pledged. To know more, check out the latest shareholding pattern of PFIZER.
What else is happening in the markets today? Dig in...
On Monday, Indian share markets failed to keep up early gains and ended marginally lower.
For full year, profit figures stood at Rs 29.6 bn as against Rs 19.8 bn for the previous year, reflecting a growth of 49%.
During Q4, there were many changes to the products forming part of Dr Reddy's generics and proprietary products segments.
The pandemic has opened up new opportunities for the Indian pharmaceutical sector. Which company is set to benefit from it?
For the Nifty pharma index, it seems as if bulls are losing ground as they witness multiple bearish candlestick patterns.
The strong momentum in India's IPO market is poised to continue with the market regulator approving the IPOs of three firms including PharmEasy.
More Views on NewsWe are just two months into 2022 and several penny stocks that we track have already surged 5x.
Debt free penny stocks are vital when it's a question of portfolio diversification in a volatile market. They can potentially offer good profitability in the long run.
A step-by-step method to pick the best penny stocks for the long term.
These penny stocks can become future multibaggers. Watch out for them.
Rising electricity consumption provides a lot of scope for growth. Which company has a better chance at capturing it?
More